News Biosimilars Comparable to Aflibercept in Macular Disease by Medscape • 2023/08/03 • 0 Comments Phase 3 registration trials found the comparability of two biosimilars to reference aflibercept in terms of efficacy, safety, pharmacokinetics, and immunogenicity. Medscape Medical News Full Story →